How to access Jaypirca from Saudi Arabia, the named-patient import pathway, 2026
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-13.
A Saudi Arabia patient with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy including a covalent BTK inhibitor, or with relapsed or refractory CLL/SLL after at least two prior lines including a covalent BTK inhibitor and a BCL-2 inhibitor, may receive a prescription for Jaypirca (pirtobrutinib) from their treating hematologist. Jaypirca is FDA-approved in the United States and manufactured by Eli Lilly. It is a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor administered by oral tablet. Local availability of Jaypirca in Saudi Arabia can be inconsistent: the drug may not be on every specialty pharmacy's standing formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through SFDA remains a legitimate route for the patient whose physician has already prescribed the drug.
This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.
Ask about Jaypirca in Saudi Arabia
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Jaypirca is a non-covalent, reversible BTK inhibitor. Mechanism: a small-molecule reversible inhibitor of Bruton tyrosine kinase that binds at a site that retains activity against the C481S BTK resistance mutation, which limits the durability of covalent BTK inhibitors. Dosing: 200 mg orally once daily, per FDA labeling. Baseline workup per FDA labeling includes CBC with differential, hepatitis B serology, baseline ECG, and bleeding history review. Other important warnings include serious infections including opportunistic infections, hemorrhage, cytopenias, atrial arrhythmias and ventricular tachyarrhythmias, and second primary malignancies including non-melanoma skin cancer. Your hematologist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Jaypirca legally importable into Saudi Arabia?
Yes, through the Saudi Food and Drug Authority (SFDA) named-patient and personal-use import framework, coordinated through a Saudi Arabia-licensed treating facility's pharmacy. Saudi Arabia has an established pathway for specialty medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.
The SFDA named-patient route allows a Saudi Arabia-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. Applications are typically filed through the dispensing institution's import pharmacy on the physician's behalf, with approval issued on a per-patient, per-cycle quantity basis.
How the pathway works, step by step
- Consultation with your treating hematologist. The prescribing decision is clinical. Your hematologist documents the indication, prior therapies (including the prior covalent BTK inhibitor and, for CLL/SLL, the prior BCL-2 inhibitor), and rationale for Jaypirca.
- Baseline screening. CBC with differential, hepatitis B serology, baseline ECG, and bleeding history review are confirmed and documented.
- SFDA named-patient application. Your hematologist or the facility's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure product from Eli Lilly's authorised distribution under DSCSA chain-of-custody.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your hematologist initiates therapy.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming diagnosis (r/r MCL post-cBTKi, or r/r CLL/SLL post-cBTKi and post-BCL-2 inhibitor), prior therapies, and Jaypirca as the indicated next step
- Verification of their Saudi Arabia medical licence
- A patient identifier, anonymised reference where privacy is preferred
- Documented pre-treatment screening consistent with FDA labeling (see above)
- The planned dosing regimen (200 mg orally once daily, per FDA labeling)
- A monitoring plan covering CBC at regular intervals, arrhythmia surveillance, infection vigilance, and hepatitis B reactivation monitoring
Reserve Meds provides a physician documentation kit tailored for BTK inhibitor therapies, including the templates SFDA reviewers commonly request.
Typical costs and indicative timing
Reserve Meds gives you a transparent, itemised custom quote at intake. Medicine price: quote on request. You get a written quote for your case before you commit. International logistics, SFDA documentation handling, and coordination add incremental cost. The delivered quote we issue at intake shows each line separately.
We give you a written timeline estimate for your case before you commit. Refills ship on a rolling cadence aligned to the dosing schedule.
Where Reserve Meds fits in
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Jaypirca specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
- Documentation. Regulatory package tailored for your physician and for SFDA review, including BTK inhibitor class templates.
- Logistics. Internationally tracked shipment to your named dispensing facility with tamper-evident packaging.
- Dedicated case lead. A named point of contact for your family and your physician across the full case arc.
We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating hematologist, and dispensing sits with the licensed Saudi Arabia pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across oncology, rare disease, and immunology at Saudi Arabia tertiary centers.
Will my private health insurance cover this? Cash-pay is the default posture. Some Saudi Arabia private insurers and CCHI-aligned plans reimburse named-patient imports on a case-by-case basis when the documentation package is strong. We supply documentation for your submission but do not process insurance claims.
What makes Jaypirca different from Imbruvica, Calquence, and Brukinsa? The first three are covalent BTK inhibitors. Jaypirca is non-covalent and reversible, which preserves activity against the C481S mutation that drives resistance after a covalent BTK inhibitor. Jaypirca's FDA-labeled role is specifically the post-covalent BTKi setting, not first-line BTK inhibition.
What if my physician has not filed a named-patient request before? Named-patient import is an institutional process most major Saudi Arabia tertiary centers (King Faisal Specialist Hospital and Research Centre, King Abdulaziz Medical City, and Prince Sultan Military Medical City) have encountered. Our documentation kit is written for first-time applicants and tracks what SFDA reviewers commonly ask for.
Next step
For Jaypirca coordination in Saudi Arabia, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Composite case examples. This content is for general information and does not constitute medical advice.
Frequently asked questions
How can I get Jaypirca in Saudi Arabia if it is not approved or available there?
Reserve Meds coordinates US-sourced Jaypirca for patients in Saudi Arabia through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Saudi Arabia and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Jaypirca in Saudi Arabia through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Jaypirca. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in Saudi Arabia, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Jaypirca in Saudi Arabia through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Jaypirca to a patient in Saudi Arabia?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Jaypirca to your treating physician or hospital pharmacy in Saudi Arabia, with appropriate handling for the product.
How long does it take, and what does Jaypirca in Saudi Arabia cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Jaypirca in Saudi Arabia?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.